Europe European pharma is at a turning point, with rising cost pressures, regulatory shifts, and supply chain vulnerabilities reshaping the industry. As the new president of Medicines for Europe, STADA’s Stephan Eder is now at the forefront of driving the change that Europe needs. In this new role as head of…
Mexico Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent according to a 2023 CANIFARMA and INEGI study. That makes it, on paper, appear a highly attractive sector for investment,…
Global A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access. Even the most innovative drug is useless if patients cannot afford or access it. As pharmaceutical innovation advances, market access strategies – determining who gets a drug, at what…
APAC Dengue fever is highly endemic in almost every country in Southeast Asia, meaning that Takeda – having launched its dengue vaccine in 2023 – stands to have a massive impact on health in the region. In conversation, Takeda’s Area Head for India and Southeast Asia Dion Warren outlines how Takeda’s…
Saudi Arabia Lyes Salah, General Manager of Amgen Saudi Arabia, delves into the company’s commitment to supporting Saudi Vision 2030 through innovation, strategic partnerships, and talent development. By advancing healthcare accessibility, fostering diversity, and driving digital transformation, Amgen plays a pivotal role in the Kingdom’s healthcare transformation. Success is not an…
Saudi Arabia AstraZeneca has made remarkable progress over the past three years in Saudi Arabia, gaining significant leadership in therapeutic areas like oncology and respiratory care, and expansion into rare diseases. Sameh ElFangary, Country President of AstraZeneca GCC & Pakistan shares insights into the company’s strategy and strong alignment with Saudi Arabia’s…
China Beyond political, cultural, economic, and linguistic concerns, the sheer pace of Chinese pharma’s development makes it challenging for international observers to fully grasp the sector’s intricacies, challenges, and numerous opportunities. Thankfully, in order to untangle this complex web PharmaBoardroom spoke directly to the heads of PhIRDA – the association representing…
China 2024 marks 30 years for Takeda in China, and the company has been outstripping the overall market to grow by double-digits in the country since 2020. Sean Shan discusses how he has led this remarkable trajectory, focusing on Takeda’s strategic vision, key product launches, and commitment to innovation. He highlights…
Puerto Rico Juan Ignacio Diddi, GM of BMS Puerto Rico & Caribbean, has over 20 years of experience in the pharmaceutical industry, having held various roles across Latin America before taking on the role leading BMS Puerto Rico and the Caribbean in 2022. He focuses on ensuring early access to therapies, fostering…
Switzerland Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of patients in Switzerland, but the country’s status as a global biopharmaceutical R&D hub? Major Challenges As outlined elsewhere in…
China Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, provides an in-depth analysis of the development of China’s healthcare landscape over the previous past four years. Ewert highlights key trends such as the growing role of local biopharma players, the impact of value-based pricing, and the changing…
China Deng Haoqing, President and General Manager of Chiesi China, explores the company’s strategic growth in one of the world’s most dynamic healthcare markets. Deng discusses the alignment of Chiesi’s “AIR, CARE, and RARE” focus with China’s evolving healthcare priorities, highlighting efforts to bring innovation through local and global collaborations, including…
See our Cookie Privacy Policy Here